Shareholders of BRAIN Biotech AG approved all agenda items with a broad majority at the company's 2026 Annual General Meeting for the 2024/25 financial year. Dr. Ursula La Cognata, managing partner of ybe (Your Biotech Experts Partnership), was elected to the Supervisory Board for a four-year term. She had previously been appointed by the Darmstadt Local Court as a new member effective July 11, 2025, until this meeting.
Supervisory Board Chairman Dr. Michael Majerus expressed confidence in the company's development opportunities, citing its successful product business, strong market position in contract research, expected revenues from monetization initiatives and pharmaceutical project licensing, and further product innovations from the BRAINBioIncubator segment. The company's detailed voting results and all other documents relating to the 2026 Annual General Meeting are available on the BRAIN Biotech AG website at https://www.brain-biotech-group.com/en/investors/annual-general-meeting/annual-general-meeting-2026/.
CEO Adriaan Moelker addressed the company's strategic direction, stating that the two-pillar strategy with the product-oriented BRAINBiocatalysts segment and the research-intensive BRAINBioIncubator segment remains the correct approach. This strategy enables the company to monetize investments, achieve scientifically based breakthroughs, and organically expand a profitable, scalable, enzyme-focused business. Moelker emphasized that the company's relatively small size allows for quick and flexible responses to customer needs through short communication channels, offering innovative biotechnological solutions that represent unique selling points.
The company is consolidating production and sales for enzymes and food ingredients for the baking and beverage industries at a new location in the Netherlands. This new facility, which includes a modern baking application center, laboratory, and production areas, is nearing completion. The consolidation represents a strategic move to streamline operations and enhance service delivery to key industry sectors.
BRAIN Biotech AG, the parent company of the BRAIN Biotech Group, operates as a leader in researching, developing, and producing specialty enzymes with a focus on food and life sciences industries. The company also develops microbial production strains and scalable bioprocesses for economic production of specialty enzymes and other proteins, while offering customized biological solutions for more sustainable products and efficient processes. The group operates fermentation facilities in the UK with additional production sites in continental Europe and the US.
In the 2024/25 fiscal year, the group generated revenue of €49.6 million with approximately 280 employees. The company has been listed on the Frankfurt Stock Exchange since February 9, 2016, under ticker symbol BNN. For more information about the company's operations and business segments, visit https://www.brain-biotech-group.com.
The shareholder approval and strategic developments at BRAIN Biotech AG highlight the biotechnology sector's ongoing evolution toward more specialized, customer-responsive business models. The company's emphasis on maintaining agility while pursuing growth reflects broader industry trends where smaller, focused biotechnology firms compete by offering tailored solutions and rapid innovation cycles. The consolidation of production facilities in the Netherlands demonstrates strategic positioning within key European markets for food ingredients and enzymes, potentially strengthening the company's competitive position in the baking and beverage industries. These developments matter because they illustrate how biotechnology companies are adapting their structures and strategies to capitalize on niche markets while maintaining the flexibility needed for scientific innovation and customer responsiveness in a rapidly evolving industry.
